Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial

  • García-Sanz, R.
  • Oriol, A.
  • Moreno, M.J.
  • Rubia, De La
  • Payer, A.R.
  • Hernández, M.T.
  • Palomera, L.
  • Teruel, A.I.
  • Blanchard, M.J.
  • Gironella, M.
  • Ribas, P.
  • Bargay, J.
  • Abellá, E.
  • Granell, M.
  • Ocio, E.M.
  • Ribera, J.M.
  • San Miguel, J.F.
  • Mateos, M.V.
This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 ver- sus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was dif- ferent for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunc- tion (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal compli- cations. This trial was registered in the ClinicalTrials.gov database with code NCT01087008
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

  • Medina, Alejandro|||0000-0001-5609-2969
  • Puig, Noemí|||0000-0001-7535-3861
  • Flores-Montero, Juan|||0000-0002-1119-4387
  • Jimenez, Cristina
  • Sarasquete, M. Eugenia|||0000-0001-7335-3657
  • García-Álvarez, María|||0000-0001-8864-1168
  • Prieto-Conde, Isabel|||0000-0002-2510-8355
  • Chillon, Carmen
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Gutierrez, Norma C.
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosinol, Laura
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernandez, Miguel T.
  • Gonzalez-Calle, Verónica
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Orfao, Alberto|||0000-0002-0007-7230
  • González, Marcos
  • García-Sanz, Ramón|||0000-0003-4120-2787
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09-0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06-0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.